Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2026 Earnings Call Transcript
Operator: Good morning, everybody. My name is Kelsy, and I will be your conference operator for today.
Karyopharm Therapeutics Inc. (KPTI)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Commodore Capital Egen Atkinson And Michael Kramarz | 1,950,000 | $10,861,500 | 0.63% | |
| 2. | RA Capital Management Peter Kolchinsky | 1,917,354 | $10,679,662 | 0.11% | |
| 3. | Adage Capital Management Phill Gross And Robert Atchinson | 1,806,322 | $10,061,214 | +329% | 0.02% |
| 4. | 920,000 | $5,124,400 | 0.42% | ||
| 5. | 920,000 | $5,124,400 | 0.42% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.22 | 41,140 | $49,985.10 | 45,140 | 2023-09-12 | Filing | |
| $8.60 | 23,250 | $199,991.85 | 131,802 | 2021-05-07 | Filing | |
| $7.82 | 4,000 | $31,280.00 | 4,000 | 2021-05-06 | Filing | |
| $14.54 | 7,500 | $109,012.50 | 7,500 | 2020-08-26 | Filing | |
| $33.00 | 2,000 | $66,000.00 | 3,000 | 2015-04-07 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.50 | 403 | $3,828.50 | 94,821 | 2026-05-14 | Filing | |
| $9.50 | 408 | $3,876.00 | 56,829 | 2026-05-14 | Filing | |
| $9.50 | 324 | $3,078.00 | 107,940 | 2026-05-14 | Filing | |
| $9.50 | 53 | $503.50 | 23,801 | 2026-05-14 | Filing | |
| $9.50 | 2,203 | $20,928.50 | 269,747 | 2026-05-14 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,086,900 | $6,054,033 | 0.04% | |
| 2. | 947,579 | $5,278,015 | 0% | |
| 3. | 865,000 | $4,818,050 | 0% | |
| 4. | 739,745 | $4,120,380 | 0% | |
| 5. | 500,000 | $2,785,000 | 0.14% |
News See All
RBC Flags Seasonal Pressures Impacting Karyopharm Therapeutics Inc. (KPTI) Short-Term Performance
TheFly reported on April 7 that RBC Capital reduced its price target on KPTI to $16 from $23 while maintaining an Outperform rating.
10 Best Biotech Stocks Under $10 to Buy
According to Eli Casdin, CEO of Casdin Capital, biotech is currently experiencing a momentary stop despite being in one of the best economic environments in years.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2025 Earnings Call Transcript
Operator: Good morning. My name is Ludi, and I will be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2025 Earnings Call Transcript
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2025 Earnings Call Transcript November 3, 2025Karyopharm Therapeutics Inc. misses on earnings expectations.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q2 2025 Earnings Call Transcript
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q2 2025 Earnings Call Transcript August 11, 2025Karyopharm Therapeutics Inc. misses on earnings expectations.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2025 Earnings Call Transcript
Operator: Good afternoon. My name is Chloe, and I will be your conference operator today.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2024 Earnings Call Transcript
Operator: Good morning. My name is Jewel, and I will be your conference operator today.
12 Best Penny Stocks to Invest in According to the Media
On December 24, Global Advisors’ managing partner, Tom Lee, shared his thoughts on the potential of small and mid-cap stocks in 2025.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2024 Earnings Call Transcript
Operator: Good morning. My name is Jenny, and I will be your conference operator today.
Hedge Fund Resource Center